Related Experiment Videos
[Antimicrobial activities of ceftriaxone against fresh, clinically isolated strains]
Abstract:
In order to evaluate antimicrobial activity of ceftriaxone (CTRX), minimum inhibitory concentrations (MICs) of CTRX and control drugs were determined against clinically isolated strains including those from purulent meningitis and liver and biliary tract infections in 1995. The results are summarized as follows; 1. MIC90 of CTRX was 0.05 micrograms/ml against benzylpenicillin (PCG)-insensitive Streptococcus pneumoniae or PCG-resistant S. pneumoniae and it was < or = 0.025 micrograms/ml against beta-lactamase producing strains of Haemophilus influenzae. Antimicrobial activities of CTRX against these strains were stronger than control drugs. 2. MIC distribution of CTRX was in a lower concentration range than those of ceftazidime and flomoxef against extend broad-spectrum beta-lactamase (EBLA)-producing Escherichia coli and Klebsiella pneumoniae subsp. pneumoniae. 3. These results suggested that CTRX will be effective against community-acquired pneumonia, purulent meningitis and liver & biliary tract infections.
Insights
Ceftriaxone (CTRX) demonstrates potent antimicrobial activity against resistant Streptococcus pneumoniae and beta-lactamase producing Haemophilus influenzae. It also shows favorable efficacy against common bacterial pathogens in serious infections.
Area of Science:
- Microbiology
- Infectious Diseases
- Pharmacology
Background:
- Antimicrobial resistance is a growing global health concern.
- Ceftriaxone (CTRX) is a widely used third-generation cephalosporin antibiotic.
- Evaluating CTRX activity against contemporary clinical isolates is crucial for guiding treatment.
Purpose of the Study:
- To assess the in vitro antimicrobial activity of ceftriaxone (CTRX) against clinically relevant bacterial strains.
- To compare CTRX efficacy with control antibiotics against specific pathogens.
- To determine the minimum inhibitory concentrations (MICs) for key bacterial species.
Main Methods:
- Determination of MIC90 values for CTRX and control drugs against isolated strains.
- Testing against penicillin-insensitive and resistant Streptococcus pneumoniae.
- Evaluating CTRX activity against beta-lactamase producing Haemophilus influenzae and extended broad-spectrum beta-lactamase (EBLA)-producing Enterobacteriaceae.
Main Results:
- CTRX exhibited potent activity against penicillin-resistant Streptococcus pneumoniae (MIC90 = 0.05 µg/mL) and Haemophilus influenzae (MIC90 ≤ 0.025 µg/mL).
- CTRX demonstrated lower MIC distributions compared to ceftazidime and flomoxef against EBLA-producing Escherichia coli and Klebsiella pneumoniae.
- Antimicrobial activity of CTRX was superior to control drugs for tested strains.
Conclusions:
- Ceftriaxone (CTRX) maintains significant antimicrobial efficacy against key pathogens.
- CTRX is likely to be effective in treating community-acquired pneumonia, purulent meningitis, and liver and biliary tract infections.
- These findings support the continued use of CTRX in clinical practice.